The global medical cannabis market: current state, technological innovations, and regulatory aspects of development

Authors

DOI:

https://doi.org/10.24959/nphj.26.202

Keywords:

medical cannabis; cannabinoids; medical cannabis market; dosage forms; delivery systems; medical cannabis innovations; regulation.

Abstract

Aim. To analyze the current state and main trends in the development of the global medical cannabis market, taking into account its segmentation, regulatory approaches, and pharmaceutical innovations.

Materials and methods. The study used methods of the secondary data analysis, the content analysis of scientific publications and industry analytical reports, the comparative and structural-logical analysis, as well as methods of generalization and systematization of information to identify key patterns in the development of the medical cannabis market.

Results. It has been found that the global medical cannabis market is characterized by stable growth rates due to the expansion of legislative permission for its use, an increase in demand for alternative treatment methods and the active development of pharmaceutical technologies. It has been determined that innovative dosage forms and cannabinoid delivery systems play a key role in the development of the market, which provide increased bioavailability, dosage accuracy and safety of use. It has been found that the market segmentation by cannabinoid types, routes of administration and therapeutic indications determines the structure of demand and directions of the investment activity. The impact of regulatory mechanisms and the participation of pharmaceutical companies on increasing the level of standardization and trust in medical cannabis products has been assessed.

Conclusions. The described patterns of the medical cannabis market development indicate its gradual integration into modern medical practice, provided that the evidence base is further strengthened, regulatory and legal regulation is harmonized and pharmaceutical quality standards are implemented.

References

  1. Banerjee, S., & McCormack, S. (2019). Medical cannabis for the treatment of chronic pain: A review of clinical effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health. https://www.ncbi.nlm.nih.gov/books/NBK546424/
  2. Kaidash, S., Sliesarchuk, V., Sokolova, K., & Potapova, T. (2025). Global experience with medical cannabis use: Indications and safety profile (literature review). Medical Perspectives, 30(3), 220–223. https://journals.uran.ua/index.php/2307-0404/article/view/340767
  3. Khaitovych, M. V., & Misiura, O. M. (2025). Efficacy and safety of cannabinoids in patients with neuropathic pain (literature review). Medical Science of Ukraine, 21(1), 158–166. https://doi.org/10.32345/2664-4738.1.2025.19
  4. Lekhan, V. M. (2024). Znachennia medychnoho kanabisu dlia vyrishennia problemy zabezpechennia znebolenniam paliatyvnykh khvorykh v Ukraini. Experimental and Clinical Medicine, 93(1), 87–93. https://doi.org/10.35339/ekm.2024.93.1.lvm
  5. Sic, A., George, C., Gonzalez, D. F., Tseriotis, V. S., & Knezevic, N. N. (2025). Cannabinoids in chronic pain: Clinical outcomes, adverse effects and legal challenges. Neurology International, 17(9), 141. https://doi.org/10.3390/neurolint17090141
  6. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misra, K., Rydahl, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456–2473. https://doi.org/10.1001/jama.2015.6358
  7. Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. The New England Journal of Medicine, 376(21), 2011–2020. https://doi.org/10.1056/NEJMoa1611618
  8. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies of Sciences, Engineering, and Medicine. (2017). The National Academies Press. https://doi.org/10.17226/24625
  9. Medical cannabis market report 2024–2033. (2024). IMARC Group. https://www.imarcgroup.com/medical-cannabis-market
  10. Global medical cannabis market – industry trends and forecast to 2032. (2024). Data Bridge Market Research. https://www.databridgemarketresearch.com/reports/global-medical-cannabis-market
  11. Medical marijuana market size by types (dried form, extract form), by applications and regional forecast to 2035. (2025). Global Growth Insights. https://www.globalgrowthinsights.com/market-reports/medical-marijuana-market-100975
  12. The global cannabis report. (2024). (5th ed.). Prohibition Partners. https://prohibitionpartners.com/reports/the-global-cannabis-report-5th-edition/
  13. Global medical cannabis market size by type, application, region, and forecast to 2033. (2024). Market Research Intellect. https://www.marketresearchintellect.com/product/global-medical-cannabis-market-size-and-forecast/
  14. Medical marijuana market. (2025). Market Research Future. https://www.marketresearchfuture.com/reports/medical-marijuana-market-6470
  15. European Medicines Agency. Summary of product characteristics – Sativex® (nabiximols). https://www.ema.europa.eu/en/documents/product-information/sativex-epar-product-information_en.pdf
  16. U.S. Food and Drug Administration. FDA and cannabis: research and drug approval process. https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
  17. Information for health care professionals: Cannabis and the cannabinoids. (2023). Health Canada. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners.html
  18. Medical cannabis regulation in Ukraine. (2024, March 16). https://dlf.ua/en/medical-cannabis-regulation-in-ukraine/
  19. Gruzieva, T. S., Korchevnyy, A. I., Palii, M. V., Hrechkivska, N. V., & Zaritska, N. M. (2024). Traceability and control as levers to prevent leakage from legal circulation when legalizing medical cannabis. Wiadomości Lekarskie, 77(4), 635–639. https://doi.org/10.36740/WLek202404103
  20. Stella, B., Baratta, F., Della Pepa, C., Arpicco, S., & Brusa, P. (2021). Cannabinoid formulations and delivery systems: Current and future options to treat pain. Drugs, 81(13), 1513–1557. https://doi.org/10.1007/s40265-021-01579-x
  21. Derzhavne pidpryiemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv». (2025). Derzhavna farmakopeia Ukrainy. Dopovnennia 8 (2-he vyd.). Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv.
  22. Casiraghi, A., Musazzi, U. M., Centin, G., Franzè, S., & Minghetti, P. (2021). Cannabis-based oral formulations for medical purposes. Pharmaceuticals, 14(2), 171. https://doi.org/10.3390/ph14020171
  23. Żółnowska, I., Gostyńska-Stawna, A., Jelińska, A., & Stawny, M. (2025). Cannabis medicine 2.0: Nanotechnology-based delivery systems for synthetic and chemically modified cannabinoids for enhanced therapeutic performance. Nanomaterials, 15(16), 1260. https://doi.org/10.3390/nano15161260
  24. Rebelatto, E., Schneider Rauber, G., & Caon, T. (2023). An update of nano-based drug delivery systems for cannabinoids: Biopharmaceutical aspects and therapeutic applications. International Journal of Pharmaceutics, 635, 122727. https://doi.org/10.1016/j.ijpharm.2023.122727

Downloads

Published

2026-03-31

Issue

Vol. 111 No. 1 (2026): News of Pharmacy

Section

Articles

License

Copyright (c) 2026 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.